ClinicalTrials.gg
Not yet recruitingNCT07100639SG-PRIMEUpdated Aug 3, 2025

Singapore Population Research on Integrated exposoMe & Early Menopause

An observational study in Early Menopause, sponsored by Institute for Human Development and Potential (IHDP), Singapore. Not yet recruiting. Open to female participants aged 40 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Institute for Human Development and Potential (IHDP), Singapore · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
40 Years to 50 Years
Sex
Female
01

Study summary

Brief Summary

The goal of this observational study is to learn how environmental factors, lifestyle choices, and social conditions affect the timing of menopause in Asian women aged 40-50 years living in Singapore. The main aims of the project are the following:

  • Do environmental pollutants and lifestyle exposures contribute to earlier menopause in Asian women?
  • What biological changes occur when women are exposed to harmful environmental factors during menopause transition?

Participants will be followed for 18 months and will complete questionnaires about their health history, lifestyle, diet, and environmental exposures. Participants will provide blood, urine, stool, hair, and nail samples for laboratory analysis and undergo basic health assessments including weight, blood pressure, and bone density measurements. Participants will wear activity monitors and air pollution sensors for 7 days and attend follow-up visits at 6 months, 12 months, and 18 months to track changes in their health. This data will be obtained during the baseline visit.

Read the detailed description

Detailed Description

Background and Rationale: Early menopause, defined as cessation of ovarian function before age 45, affects approximately 5-12% of women globally and is associated with increased risks of cardiovascular disease, osteoporosis, and cognitive decline. Growing evidence suggests that environmental exposures, including persistent organic pollutants, air pollution, and endocrine-disrupting chemicals, may accelerate ovarian aging and contribute to earlier menopausal timing. The exposome concept involves the totality of environmental exposures experienced by individuals throughout their lifetimes, including chemical, physical, biological, and social factors.

Study Hypothesis We hypothesize that combined exposure to environmental pollutants, lifestyle factors, and social conditions accelerates biological aging processes and leads to earlier menopause onset in women. These exposome effects are mediated through changes in gene expression patterns, metabolic profiles, and gut microbiome composition, ultimately increasing the risk of adverse health outcomes.

Study Design: This is a prospective observational cohort study employing a longitudinal design with 18-month follow-up. The study integrates comprehensive exposome assessment with multi-omics profiling to investigate the complex relationships between environmental factors and menopausal health outcomes in a multi-ethnic Asian population.

Population and Setting: Four hundred women aged 40-50 years will be recruited from diverse communities across Singapore. Participants must have experienced no menstruation for the last 2 months or irregular menstrual cycles in the last 6 months, be proficient in English, and plan to reside in Singapore for the study duration. The study will include Chinese, Malay, and Indian ethnicities reflecting Singapore's demographic composition.

Data Collection Methods: Exposome characterization includes external environmental monitoring through air pollution assessment, climate data collection, green space quantification, and personal exposure measurement using wearable devices. Biological samples including blood, urine, stool, hair, and nail specimens will undergo multi-omics analysis encompassing metabolomics, lipidomics, epigenetics, transcriptomics, and microbiome profiling. Clinical assessments include anthropometric measurements, blood pressure monitoring, and bone density evaluation.

Analysis Plan: Multi-layered analytical approaches will include exposome-wide association studies, machine learning techniques for predictive modeling, and causal inference methods to examine relationships between exposome factors and menopausal outcomes. Advanced statistical methods will account for the high-dimensional nature of exposome data and temporal relationships between exposures and health outcomes.

Eligibility Criteria

Inclusion Criteria:

  • Female participants aged 40-50 years
  • No menstruation for the last 2 months or irregular menstrual cycles in the last 6 months
  • Chinese, Malay, or Indian ethnicity
  • Proficient in English language
  • Planning to reside in Singapore for next 2 years
  • Willing to provide informed consent and comply with study procedures

Exclusion Criteria:

  • In menopause (12 consecutive months without menstruation)
  • Currently pregnant or planning to conceive
  • History of bilateral oophorectomy and/or hysterectomy
  • Currently receiving hormone therapy, including estradiol replacement therapy or oral contraceptives
  • Diagnosed with premature ovarian insufficiency before 40 years of age
  • Diagnosis of autoimmune conditions and/or chromosomal abnormalities known to affect ovarian function
  • Diagnosis of severe cognitive impairment and/or mental disorders
  • Received cancer treatment in the past 12 months

Target Sample Size 400 participants

02

Conditions studied

  • Early Menopause

Keywords

  • early menopause
  • environment
  • pollution
  • exposome
03

In context

Primary Ovarian Insufficiency

182 studies on the registry are indexed under Primary Ovarian Insufficiency; 49 are open to participants now.

This study's planned enrollment of 400 is above the median of 100 across 61 observational studies indexed under Primary Ovarian Insufficiency.

Browse Primary Ovarian Insufficiency studies →

Lead sponsor

Institute for Human Development and Potential (IHDP), Singapore is the lead sponsor of 24 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Women experiencing perimenopausal transition characterized by irregular menstrual patterns and hormonal fluctuations, stratified by age groups (40-45 years and 46-50 years) and ethnicity to ensure representative sampling of Singapore's multi-ethnic population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female participants aged 40-50 years No menstruation for the last 2 months or irregular menstrual cycles in the last 6 months Chinese, Malay, or Indian ethnicity Proficient in English language Planning to reside in Singapore for next 2 years Willing to provide and comply with study procedures

Exclusion criteria

Exclusion Criteria:

In menopause (12 consecutive months without menstruation) Currently pregnant or planning to conceive History of bilateral oophorectomy and/or hysterectomy Currently receiving hormone therapy, including estradiol replacement therapy or oral Diagnosed with premature ovarian insufficiency before 40 years of age Diagnosis of conditions and/or chromosomal abnormalities known to affect ovarian function Diagnosis of severe cognitive impairment and/or mental disorders Received cancer treatment in the past 12 months

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • SG-PRIME

    no interventions

06

What researchers measure

Primary outcomes

  1. Early menopause

    Time frame: 18 months

  2. Time to menopause onset

    • Menopausal symptom severity score using standardized assessment tools

    Time frame: 18 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2025; primary completion for Mar 2028, 31 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2025
First posted
Aug 3, 2025
StartEst.
Aug 6, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Apr 1, 2028
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07100639
Lead sponsor
Institute for Human Development and Potential (IHDP), Singapore
Responsible party
Kothandaraman Narasimhan, Ph.D. (Principal Investigator, Institute for Human Development and Potential (IHDP), Singapore) — Principal investigator
First posted
Aug 3, 2025
Start date
Aug 6, 2025 (estimated)
Primary completion
Mar 31, 2028 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Aug 3, 2025

Study contacts

Narasimhan Kothandaraman, Ph.D
Contact
Kothandaraman_Narasimhan@sics.-astar.edu.sg
+65 64074057

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion